The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Advances deployment of mRNA technology across vaccines and therapeutics development
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
This is the first drug to receive a recommendation for this preventative indication in the European Union
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Subscribe To Our Newsletter & Stay Updated
